Sinphar Kicks Off Construction of New Cancer Reagent Factory

Taipei, May 15, 2012 (CENS)--Sinphar Pharmaceutical Co., Ltd., a major pharmaceutical maker in Taiwan, recently kicked off construction of a new factory focusing on producing cancer reagents.

C.W. Lee, Sinphar's chairman, said that total investment in the new facility reaches around NT$500 million (US$16.7 million). The new factory would be Taiwan's first automatic cancer-reagent production factory. He added that the new factory is scheduled to start mass production in April 2013, and the maximum annual capacity would be five million injection reagents.

Currently, Lee claimed, Sinphar owns a 70% share of domestic breast- and oophoritis cancer reagent market, while its contract production business for a major Japanese customer has been steadily increasing. So, the chairman said, the total investment in the new factory is expected to be returned by 2016.

Lee stressed that the new factory totally meet the most stringent standards promulgated by the U.S., Japan and European Union. And the production lines at the new facility are totally isolated from humans and highly active materials.

Sinphar has been aggressively venturing into new-drug development in recent years. Currently, the firm has had four new drugs under Food and Drug Administration (FDA) human clinical trials. The firm mainly focuses on herbal-extraction drugs.